Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas

Cancer Research

Volumn 64, Issue 15, 2004, Pages 5270-5282

  Hoek, Keith ^a,d   Rimm, David L ^a   Williams, Kenneth R ^a   Zhao, Hongyu ^a   Ariyan, Stephan ^a   Liu, Aiping ^a   Kluger, Harriet M ^a   Berger, Aaron J ^a   Cheng, Elaine ^a   Trombetta, E Sergio ^a   Wu, Terence ^a   Niinobe, Michio ^b   Yoshikawa, Kazuaki ^b   Hannigan, Gregory E ^c   Halaban, Ruth ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OSAKA UNIVERSITY   (Japan)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR RECEPTOR; HELIX LOOP HELIX PROTEIN; NOTCH RECEPTOR; UBIQUITIN;

ARTICLE; CANCER STAGING; CARBOXY TERMINAL SEQUENCE; CELL TRANSFORMATION; CONTROLLED STUDY; CPG ISLAND; DNA FINGERPRINTING; DNA METHYLATION; DNA MICROARRAY; EMBRYO DEVELOPMENT; EPIDERMIS CELL; GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC SELECTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; MELANOCYTE; MELANOMA; MESENCHYME CELL; NECDIN GENE; PRADER WILLI SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; STRAIN IDENTIFICATION; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; VALIDATION PROCESS;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; COHORT STUDIES; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MELANOCYTES; MELANOMA; MICE; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; SURVIVAL RATE; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; TWIST TRANSCRIPTION FACTOR; UBIQUITIN THIOLESTERASE;

EID: 3442894137     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0731     Document Type: Article

References (124)

1. Cannon-Albright LA, Kamb A, Skolnick M. A review of inherited predisposition to melanoma. Semin Oncol 1996;23:667-72.
2. Dracopoli NC, Fountain JW. CDKN2 mutations in melanoma. Cancer Surv 1996;26:115-32.
3. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Wash DC) 1994;264:436-40.
4. Kamb A, Shattuck-Eidens D, Eeles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994;8:23-6.
5. Tucker MA, Goldstein AM. Melanoma etiology: where are we? Oncogene 2003;22:3042-52.
6. INK4a expression in uveal melanoma. Cancer Res 2001;61:5303-6.
7. Reed JA, Loganzo F, Shea CR, et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995;55:2713-8.
8. Piccinin S, Doglioni C, Maestro R, et al. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression. Int J Cancer 1997;74:26-30.
9. Alonso SR, Ortiz P, Pollan M, et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 2004;164:193-203.
10. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature (Lond) 2002;417:949-54.
11. Alsina J, Gorsk DH, Germino FJ, et al. Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma. Clin Cancer Res 2003;9:6419-25.
12. Halaban R, Cheng E, Smicun Y, Germino J. Deregulated E2F transcriptional activity in autonomously growing melanoma cells. J Exp Med 2000;191:1005-15.
13. Seftor RE, Seftor EA, Hendrix MJ. Molecular role(s) for integrins in human melanoma invasion. Cancer Metastasis Rev 1999;18:359-75.
14. Kaelin WG Jr. E2F1 as a target: promoter-driven suicide and small molecule modulators. Cancer Biol Ther 2003;2:S48-54.
15. Ma D, Zhou P, Harbour JW. Distinct mechanisms for regulating the tumor suppressor and antiapoptotic functions of Rb. J Biol Chem 2003;278:19358-66.
16. Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 1998;58:2170-5.
17. Bastian BC, Kashani-Sabet M, Hamm H, et al. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res 2000;60:1968-73.
18. Harvell JD, Bastian BC, LeBoit PE. Persistent (recurrent) spitz nevi: a histopathologic, immunohistochemical, and molecular pathologic study of 22 cases. Am J Surg Pathol 2002;26:654-61.
19. Sauter ER, Yeo UC, von Stemm A, et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 2002;62:3200-6.
20. Bastian BC, Xiong J, Frieden IJ, et al. Genetic changes in neoplasms arising in congenital melanocytic nevi: differences between nodular proliferations and melanomas. Am J Pathol 2002;161:1163-9.
21. Balazs M, Adam Z, Treszl A, et al. Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization. Cytometry 2001;46:222-32.
22. Bastian BC, Olshen AB, LeBoit PE, Pinkel D. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 2003;163:1765-70.
23. Bastian BC. Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer. Oncogene 2003;22:3081-6.
24. Takata M, Maruo K, Kageshita T, et al. Two cases of unusual acral melanocytic tumors: illustration of molecular cytogenetics as a diagnostic tool. Hum Pathol 2003;34:89-92.
25. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature (Lond) 2000;406:536-40.
26. Weeraratna AT, Jiang Y, Hosteller G, et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 2002;1:279-88.
27. Weeraratna AT, Becker D, Carr KM, et al. Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. Oncogene 2004;23:2264-74.
28. von Willebrand M, Zacksenhaus E, Cheng E, Glazer P, Halaban R. The tyrphostin AG1024 accelerates the degradation of phosphorylated forms of retinoblastoma protein (pRb) and restores pRb tumor suppressive function in melanoma cells. Cancer Res 2003;63:1420-9.
29. Cuomo M, Nicotra MR, Apollonj C, et al. Production and characterization of the murine monoclonal antibody 2G10 to a human T4-tyrosinase epitope. J Investig Dermatol 1991;96:446-51.
30. Zakut R, Perlis R, Eliyahu S, et al. KJT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells. Oncogene 1993;8:2221-9.
31. Halaban R, Miglarese MR, Smicun Y, Puig S. Melanomas, from the cell cycle point of view. Int J Mol Med 1998;1:419-25.
32. Halaban R. The regulation of normal melanocyte proliferation. Pigment Cell Res 2000;13:4-14.
33. Tamura A, Halaban R, Moellmann G, et al. Normal murine melanocytes in culture. In Vitro Cell Dev Biol 1987;23:519-22.
34. Giambernardi TA, Rodeck U, Klebe RJ. Bovine serum albumin reverses inhibition of RT-PCR by melanin. Biotechniques 1998;25:564-6.
35. Eisen MB, Brown PO. DNA arrays for analysis of gene expression. Methods Enzymol 1999:303:179-205.
36. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289-300.
37. Heyer LJ, Kruglyak S, Yooseph S. Exploring expression data: identification and analysis of coexpressed genes. Genome Res 1999;9:1106-15.
38. Ausubel FM, Brent R, Kingston R, Moore RE, Moore DD, Seidman JG, Smith JA, Struhl K. Current protocols in molecular biology. New York: John Wiley & Sons: 1995.
39. Niinobe M, Koyama K, Yoshikawa K. Cellular and subcellular localization of necdin in fetal and adult mouse brain. Dev Neurosci 2000;22:310-9.
40. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8:1323-8.
41. Kielhorn E, Provost E, Olsen D, et al. Tissue microarray-based analysis shows phospho-beta-catenin expression in malignant melanoma is associated with poor outcome. Int J Cancer 2003;103:652-6.
42. Berger AJ, Kluger HM, Li N, et al. Subcellular localization of activating transcription factor 2 (ATF2) in melanoma specimens predicts patient survival. Cancer Res 2003;63:8103-7.
43. Henderson AM, Wang SJ, Taylor AC, Aitkenhead M, Hughes CC. The basic helix-loop-helix transcription factor HESR1 regulates endothelial cell tube formation. J Biol Chem 2001;276:6169-76.
44. Hu B, Wang S, Zhang Y, et al. A nuclear target for interleukin-1alpha: interaction with the growth suppressor necdin modulates proliferation and collagen expression. Proc Natl Acad Sci USA 2003;100:10008-13.
45. Halaban R, Patton RS, Cheng E, et al. Abnormal acidification of melanoma cells induces tyrosinase retention in the early secretory pathway. J Biol Chem 2002;277:14821-8.
46. Padovan E, Terracciano L, Certa U, et al. Interferon stimulated gene 15 constitutively produced by melanoma cells induces e-cadherin expression on human dendritic cells. Cancer Res 2002;62:3453-8.
47. Van Belle PA, Elenitsas R, Satyamoorthy K, et al. Progression-related expression of betaS integrin in melanomas and nevi. Hum Pathol 1999;30:562-7.
48. Easty DJ, Herlyn M, Bennett DC. Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis. Int J Cancer 1995;60:129-36.
49. Reed JA, McNutt NS, Prieto VG, Albino AP. Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression. Am J Pathol 1994;145:97-104.
50. Bodey B, Kaiser HE, Goldfarb RH. Immunophenotypically varied cell subpopulations in primary and metastatic human melanomas. Monoclonal antibodies for diagnosis, detection of neoplastic progression and receptor directed immunotherapy. Anticancer Res 1996;16:517-31.
51. Easty DJ, Bennett DC. Protein tyrosine kinases in malignant melanoma. Melanoma Res 2000;10:401-11.
52. Garbe C, Leiter U, Ellwanger U, et al. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer (Phila) 2003;97:1737-45.
53. Li G, Herlyn M. Dynamics of intercellular communication during melanoma development. Mol Med Today 2000;6:163-9.
54. Herlyn M, Berking C, Li G, Satyamoonhy K. Lessons from melanocyte development for understanding the biological events in naevus and melanoma formation. Melanoma Res 2000;10:303-12.
55. Wesley UV, Albino AP, Tiwari S, Houghton AN. A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J Exp Med 1999;190:311-22.
56. Maier MM, Gessler M. Comparative analysis of the human and mouse Hey1 promoter: Hey genes are new Notch target genes. Biochem Biophys Res Commun 2000;275:652-60.
57. Halaban R, Kwon BS, Ghosh S, Delli Bovi P, Baird A. bFGF as an autocrine growth factor for human melanomas. Oncogene Res 1988;3:177-86.
58. Albino AP, Davis BM, Nanus D. Induction of growth factor RNA expression in human malignant melanoma: markers of transformation. Cancer Res 1991;51:4815-20.
59. Yayon A, Ma YS, Safran M, Klagsbrun M, Halaban R. Suppression of autocrine cell proliferation and tumorigenesis of human melanoma cells and fibroblast growth factor transformed fibroblasts by a kinase-deficient FGF receptor 1: evidence for the involvement of Src- family kinases. Oncogene 1997;14:2999-3009.
60. Becker D, Lee PL, Rodeck U, Herlyn M. Inhibition of the fibroblast growth factor receptor 1 (FGFR-1) gene in human melanocytes and malignant melanomas leads to inhibition of proliferation and signs indicative of differentiation. Oncogene 1992;7:2303-13.
61. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002;188:22-32.
62. Sigalotti L, Coral S, Nardi G, et al. Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma. J Immunother 2002;25:16-26.
63. Coral S, Sigalotti L, Altomonte M, et al. 5-Aza-2′-deoxycytidine- induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res 2002;8:2690-5.
64. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S. Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol 2003;24:335-42.
65. Metcalf D. The unsolved enigmas of leukemia inhibitory factor. Stem Cells 2003;21:5-14.
66. Mori M, Yamaguchi K, Honda S, et al. Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor. Cancer Res 1991;51:6656-9.
67. Paglia D, Oran A, Lu C, et al. Expression of leukemia inhibitory factor and interleukin-11 by human melanoma cell lines: LIF, IL-6, and IL-11 are not coregulated. J Interferon Cytokine Res 1995;15:455-60.
68. Bamberger AM, Jenatschke S, Schulte HM, Loning T, Bamberger MC. Leukemia inhibitory factor (LIF) stimulates the human HLA-G promoter in JEG3 choriocarcinoma cells. J Clin Endocrinol Metab 2000;85:3932-6.
69. Dell'Angelica EC. Melanosome biogenesis: shedding light on the origin of an obscure organelle. Trends Cell Biol 2003;13:503-6.
70. Seabra MC, Mules EH, Hume AN. Rab GTPases, intracellular traffic and disease. Trends Mol Med 2002;8:23-30.
71. Hammer JA III, Wu XS. Rabs grab motors: defining the connections between Rab GTPases and motor proteins. Curr Opin Cell Biol 2002;14:69-75.
72. Lukashok SA, Tarassishin L, Li Y, Horwitz MS. An adenovirus inhibitor of tumor necrosis factor alpha-induced apoptosis complexes with dynein and a small GTPase. J Virol 2000;74:4705-9.
73. Zhang H, Palmer R, Gao X, et al. Transcriptional activation of placental growth factor by the forkhead/winged helix transcription factor FoxD1. Curr Biol 2003;13:1625-9.
74. Forlani S, Lawson KA, Deschamps J. Acquisition of Hox codes during gastrulation and axial elongation in the mouse embryo. Development (Cambr) 2003;130:3807-19.
75. Herlyn M, Balaban G, Bennicelli J, et al. Primary melanoma cells of the vertical growth phase: similarities to metastatic cells. J Natl Cancer Inst (Bethesda) 1985;74:283-9.
76. Halaban R, Ghosh S, Duray P, Kirkwood JM, Lerner AB. Human melanocytes cultured from nevi and melanomas. J Investig Dermatol 1986;87:95-101.
77. Greene JM, Li YL, Yourey PA, et al. Identification and characterization of a novel member of the fibroblast growth factor family. Eur J Neurosci 1998;10:1911-25.
78. Leung-Hagesteijn C, Mahendra A, Naruszewicz I, Hannigan GE. Modulation of integrin signal transduction by ILKAP, a protein phosphatase 2C associating with the integrin-linked kinase, ILK1. EMBO J 2001;20:2160-70.
79. Tan C, Cruet-Hennequart S, Troussard A, et al. Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell 2004;5:79-90.
80. Dai DL, Makretsov N, Campos EI, et al. Increased expression of integrin-linked kinase is correlated with melanoma progression and poor patient survival. Clin Cancer Res 2003;9:4409-14.
81. Kumar AS, Naruszewicz I, Wang P, Leung-Hagesteijn C, Hannigan GE. ILKAP regulates ILK signaling and inhibits anchorage independent growth. Oncogene 2004;23:3454-61.
82. Tuominen H, Kallioinen M. Increased tenascin expression in melanocytic tumors. J Cutan Pathol 1994;21:424-9.
83. Tuominen H, Pollanen R, Kallioinen M. Multicellular origin of tenascin in skin tumors-an in situ hybridization study. J Cutan Pathol 1997;24:590-6.
84. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature (Lond) 2000;406:532-5.
85. Burchardt ER, Hein R, Bosserhoff AK. Laminin, hyaluronan, tenascin-C and type VI collagen levels in sera from patients with malignant melanoma. Clin Exp Dermatol 2003;28:515-20.
86. Walker TM, Van Ginkel PR, Gee RL, et al. Expression of angiogenic factors Cyr61 and tissue factor in uveal melanoma. Arch Ophthalmol 2002;120:1719-25.
87. Kunz M, Moeller S, Koczan D, et al. Mechanisms of hypoxic gene regulation of angiogenesis factor Cyr61 in melanoma cells. J Biol Chem 2003;25:45651-60.
88. Lin MT, Chang CC, Chen ST, et al. Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaB-dependent XIAP up-regulation. J Biol Chem 2004;279:24015-23.
89. Huang J, Frischer JS, Serur A, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 2003;100:7785-90.
90. Schiedeck TH, Wellm C, Roblick LIJ, Broll R, Bruch HP. Diagnosis and monitoring of colorectal cancer by L6 blood serum polymerase chain reaction is superior to carcinoembryonic antigen-enzyme-linked immunosorbent assay. Dis Colon Rectum 2003;46:818-25.
91. Kaneko R, Tsuji N, Kamagata C, et al. Amount of expression of the tumor-associated antigen L6 gene and transmembrane 4 superfamily member 5 gene in gastric cancers and gastric mucosa. Am J Gastroenterol 2001;96:3457-8.
92. Seykora JT, Jih D, Elenitsas R, Horng WH, Elder DE. Gene expression profiling of melanocytic lesions. Am J Dermatopathol 2003;25:6-11.
93. Fitzgerald K, Harrington A, Leder P. Ras pathway signals are required for notch-mediated oncogenesis. Oncogene 2000;19:4191-8.
94. Nam Y, Aster JC, Blacklow SC. Notch signaling as a therapeutic target. Curr Opin Chem Biol 2002;6:501-9.
95. Carr DJ, Al-khatib K, James CM, Silverman R. Interferon-beta suppresses herpes simplex virus type 1 replication in trigeminal ganglion cells through an RNase L-dependent pathway. J Neuroimmunol 2003;141:40-6.
96. Al-khatib K, Williams BR, Silverman RH, Halford W, Carr DJ. The murine double-stranded RNA-dependent protein kinase PKR and the murine 2′,5′-oligoadenylate synthetase-dependent RNase L are required for IFN-beta-mediated resistance against herpes simplex virus type 1 in primary trigeminal ganglion culture. Virology 2003;313:126-35.
97. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001;14:778-809.
98. Silverman RH. Implications for RNase L in prostate cancer biology. Biochemistry 2003;42:1805-12.
99. Karpf AR, Jones DA. Reactivating the expression of methylation silenced genes in human cancer. Oncogene 2002;21:5496-503.
100. Chawla-Sarkar M, Lindner DJ, Liu YF, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003;8:237-49.
101. Kulaeva OI, Draghici S, Tang L, et al. Epigenetic silencing of multiple interferon pathway genes after cellular immortalization. Oncogene 2003;22:4118-27.
102. Gray RJ, Pockaj BA, Kirkwood JM. An update on adjuvant interferon for melanoma. Cancer Control 2002;9:16-21.
103. Kirkwood JM, Richards T, Zarour HM, et al. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer (Phila) 2002;95:1101-12.
104. Chung KK, Dawson VL, Dawson TM. New insights into Parkinson's disease. J Neurol 2003;250:III15-24.
105. Davenport TG, Jerome-Majewska LA, Papaioannou VE. Mammary gland, limb and yolk sac defects in mice lacking Tbx3, the gene mutated in human ulnar mammary syndrome. Development (Camb) 2003;130:2263-73.
106. Lingbeek ME, Jacobs JJ, van Lohuizen M. The T-box repressors TBX2 and TBX3 specifically regulate the tumor suppressor gene p14ARF via a variant T-site in the initiator. J Biol Chem 2002;277:26120-7.
107. Maestro R, Dei Tos AP, Hamamori Y, et al. Twist is a potential oncogene that inhibits apoptosis. Genes Dev 1999;13:2207-17.
108. Brummelkamp TR, Kortlever RM, Lingbeek M, et al. TBX-3, the gene mutated in ulnar-mammary syndrome, is a negative regulator of p19ARF and inhibits senescence. J Biol Chem 2002;277:6567-72.
109. Carlson H, Ota S, Song Y, Chen Y, Hurlin PJ. Tbx3 impinges on the p53 pathway to suppress apoptosis, facilitate cell transformation and block myogenic differentiation. Oncogene 2002;21:3827-35.
110. Wang X, Ling MT, Guan XY, et al. Identification of a novel function of TWIST, a bHLH protein, in the development of acquired Taxol resistance in human cancer cells. Oncogene 2004;23:474-82.
111. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature (Lond) 1998;396:177-80.
112. Sherr CJ. Principles of tumor suppression. Cell 2004;116:235-46.
113. Kuwako KI, Taniura H, Yoshikawa K. Necdin-related MAGE proteins differentially interact with the E2F1 transcription factor and the p75 neurotrophin receptor. J Biol Chem 2004;279:1703-12.
114. Gillanders E, Hank Juo SH, Holland EA, et al. Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet 2003;73:301-13.
115. Pollock PM, Welch J, Hayward NK. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development. Cancer Res 2001;61:1154-61.
116. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylalion and chromatin alterations in human tumours. J Pathol 2002;196:1-7.
117. Flagiello D, Poupon MF, Cillo C, Dutrillaux B, Malfoy B. Relationship between DNA methylation and gene expression of the HOXB gene cluster in small cell lung cancers. FEBS Lett 1996;380:103-7.
118. Karpf AR, Lasek AW, Ririe TO, et al. Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine. Mol Pharmacol 2004;65:18-27.
119. Ballestar E, Paz MF, Valle L, et al. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J 2003;22:6335-45.
120. Lu R, Au WC, Yeow WS, Hageman N, Pitha PM. Regulation of the promoter activity of interferon regulatory factor-7 gene. Activation by interferon and silencing by hypermethylation. J Biol Chem 2000;275:31805-12.
121. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002;18:1427-31.
122. Robert MF, Morin S, Beaulieu N, et al. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 2003;33:61-5.
123. Reid GK, Besterman JM, MacLeod AR. Selective inhibition of DNA methyltransferase enzymes as a novel strategy for cancer treatment. Curr Opin Mol Ther 2002;4:130-7.
124. Goffin J, Eisenhauer E. DNA methyltransferase inhibitors-state of the art. Ann Oncol 2002;13:1699-716.